Suchergebnisse - "Hayden, Frederick G."

PubPharm (129)

1

Oral Favipiravir Exposure and Pharmacodynamic Effects in Outpatient Adults with Acute Influenza

enthalten in: The Journal of infectious diseases | 2023

von Hayden, F. | Lenk, R. | Epstein, C. | +1

2

Clinical and Economic Impact of COVID-19 on Agricultural Workers, Guatemala1

enthalten in: Emerging infectious diseases | 2022

von Olson, D. | Calvimontes, D. | Lamb, M. | +25

3

Favipiravir Treatment of Uncomplicated Influenza in Adults : Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials

enthalten in: The Journal of infectious diseases | 2022

von Hayden, F. | Lenk, R. | Stonis, L. | +3

4

Heterogeneity of treatment effect of interferon-β1b and lopinavir-ritonavir in patients with Middle East respiratory syndrome by cytokine levels

enthalten in: Scientific reports | 2022

von Arabi, Y. | Asiri, A. | Assiri, A. | +21

5

Reducing Influenza Virus Transmission : The Potential Value of Antiviral Treatment

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2022

von Hayden, F. | Asher, J. | Cowling, B. | +10

6

Influenza polymerase inhibitor resistance : Assessment of the current state of the art - A report of the isirv Antiviral group

enthalten in: Antiviral research | 2021

von Ison, M. | Hayden, F. | Hay, A. | +4

7

Baloxavir Treatment in Adolescents With Acute Influenza : Subgroup Analysis From the CAPSTONE-1 Trial

enthalten in: Journal of the Pediatric Infectious Diseases Society | 2021

von Portsmouth, S. | Hayden, F. | Kawaguchi, K. | +5

8

Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances

enthalten in: Cold Spring Harbor perspectives in medicine | 2021

von Beigel, J. | Hayden, F.

9

Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU : First Update

enthalten in: Critical care medicine | 2021

von Alhazzani, W. | Evans, L. | Alshamsi, F. | +44

CommentIn: Crit Care Med. 2022 Jan 1;50(1):e95-e96. - PMID 34407038

10

Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza

enthalten in: EBioMedicine | 2020

von Wang, Y. | Zhong, W. | Salam, A. | +29

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[13]